Search Results - "O'Dorisio, Thomas"

Technical Note: Single time point dose estimate for exponential clearance by Madsen, Mark T., Menda, Yusuf, O'Dorisio, Thomas M., O'Dorisio, M. Sue

“…Objective Although personalized dosimetry may be desirable for radionuclide therapy treatments, the multiple time samples required to determine the total…”
Get full text

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors by Halfdanarson, Thorvardur R., Strosberg, Jonathan R., Tang, Laura, Bellizzi, Andrew M., Bergsland, Emily K., O'Dorisio, Thomas M., Halperin, Daniel M., Fishbein, Lauren, Eads, Jennifer, Hope, Thomas A., Singh, Simron, Salem, Riad, Metz, David C., Naraev, Boris G., Reidy-Lagunes, Diane L., Howe, James R., Pommier, Rodney F., Menda, Yusuf, Chan, Jennifer A.

“…This article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine…”
Get full text

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues by Anthony, Lowell B., O'Dorisio, Thomas M.

“…Octreotide acetate (octreotide) is the most prescribed and most studied somatostatin congener, or analog, for gastroenteropancreatic neuroendocrine tumors…”
Get full text

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial by Yao, James C, Lombard-Bohas, Catherine, Baudin, Eric, Kvols, Larry K, Rougier, Philippe, Ruszniewski, Philippe, Hoosen, Sakina, St Peter, Jessica, Haas, Tomas, Lebwohl, David, Van Cutsem, Eric, Kulke, Matthew H, Hobday, Timothy J, O'Dorisio, Thomas M, Shah, Manisha H, Cadiot, Guillaume, Luppi, Gabriele, Posey, James A, Wiedenmann, Bertram

“…PURPOSE No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral…”
Get full text

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach by Gelhorn, Heather L., PhD, Kulke, Matthew H., MD, O’Dorisio, Thomas, MD, Yang, Qi M., PhD, Jackson, Jessica, BS, Jackson, Shanna, MBA, Boehm, Kristi A., MS, Law, Linda, MD, Kostelec, Jacqueline, BA, Auguste, Priscilla, MHS, Lapuerta, Pablo, MD

“…Abstract Purpose Telotristat etiprate, a tryptophan hydroxylase inhibitor, was previously evaluated in a Phase II randomized, placebo-controlled clinical trial…”
Get full text

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study by Kvols, Larry K, Oberg, Kjell E, O'Dorisio, Thomas M, Mohideen, Pharis, de Herder, Wouter W, Arnold, Rudolf, Hu, Ke, Zhang, Yilong, Hughes, Gareth, Anthony, Lowell, Wiedenmann, Bertram

“…Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst1,2,3) and…”
Get full text

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide by Kulke, Matthew H, O'Dorisio, Thomas, Phan, Alexandria, Bergsland, Emily, Law, Linda, Banks, Phillip, Freiman, Joel, Frazier, Kenny, Jackson, Jessica, Yao, James C, Kvols, Larry, Lapuerta, Pablo, Zambrowicz, Brian, Fleming, Douglas, Sands, Arthur

“…Serotonin produced by neuroendocrine tumors is believed to be a principal cause of the diarrhea in carcinoid syndrome. We assessed the safety and efficacy of…”
Get full text

The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum by Anthony, Lowell B, Strosberg, Jonathan R, Klimstra, David S, Maples, William J, O'Dorisio, Thomas M, Warner, Richard R P, Wiseman, Gregory A, Benson, 3rd, Al B, Pommier, Rodney F

“…Neuroendocrine tumors (NETs) of the distal colon and rectum are also known as hindgut carcinoids based on their common embryologic derivation. Their annual…”
Get full text

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients by Theiler, Deborah, Cattaneo, Marco, Dierickx, Lawrence O, Igaz, Peter, Grozinsky-Glasberg, Simona, Bournaud, Claire, O'Dorisio, Thomas, O'Dorisio, M Sue, Wild, Damian, Christ, Emanuel, Nicolas, Guillaume P

“…Peptide receptor radionuclide therapy (PRRT) is a well-established treatment in somatostatin receptor-expressing neuroendocrine tumours (NETs). The safety and…”
Get full text

Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers by Fath, Melissa A., Liu, Dijie, Ewald, Jordan T., Robles-Planells, Claudia, Tomanek-Chalkley, Ann M., Graves, Stephen A., Howe, James R., O'Dorisio, Thomas M., Rastogi, Prerna, Bellizzi, Andrew M., O'Dorisio, M Sue, Menda, Yusuf, Spitz, Douglas R.

“…Intermediate to high-grade lung neuroendocrine tumors (NETs; i.e., atypical carcinoid tumors) and neuroendocrine carcinomas (NECs) are currently difficult to…”
Get full text

Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? by Maxwell, Jessica E., MD, MBA, Sherman, Scott K., MD, O'Dorisio, Thomas M., MD, Bellizzi, Andrew M., MD, Howe, James R., MD

“…Introduction Neuroendocrine tumors (NETs) frequently metastasize to the liver. Operative debulking offers symptomatic relief and improved survival; however,…”
Get full text

Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea by BENSON, Al B, AJANI, Jaffer A, WADLER, Scott, CATALANO, Robert B, ENGELKING, Constance, KORNBLAU, Steven M, MARTENSON, James A, MCCALLUM, Richard, MITCHELL, Edith P, O'DORISIO, Thomas M, VOKES, Everett E

“…To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. An expert multidisciplinary…”
Get full text

Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas by Lee, John P, Hung, Yin P, O'Dorisio, Thomas M, Howe, James R, Hornick, Jason L, Bellizzi, Andrew M

“…Aims Paired‐like homeobox 2b (PHOX2B) is a transcription factor with expression outside of the central nervous system restricted to neurons and chromaffin…”
Get full text

Long‐Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome by Anthony, Lowell B., Kulke, Matthew H., Caplin, Martyn E., Bergsland, Emily, Öberg, Kjell, Pavel, Marianne, Hörsch, Dieter, Warner, Richard R.P., O'Dorisio, Thomas M., Dillon, Joseph S., Lapuerta, Pablo, Kassler‐Taub, Kenneth, Jiang, Wenjun

“…Background Patients with neuroendocrine tumors (NETs) and carcinoid syndrome experience considerable morbidity and mortality; carcinoid syndrome may be…”
Get full text

Clinical, Diagnostic, and Treatment Characteristics of SDHA -Related Metastatic Pheochromocytoma and Paraganglioma by Jha, Abhishek, de Luna, Kristine, Balili, Charlene Ann, Millo, Corina, Paraiso, Cecilia Angela, Ling, Alexander, Gonzales, Melissa K, Viana, Bruna, Alrezk, Rami, Adams, Karen T, Tena, Isabel, Chen, Alice, Neuzil, Jiri, Raygada, Margarita, Kebebew, Electron, Taieb, David, O'Dorisio, M Sue, O'Dorisio, Thomas, Civelek, Ali Cahid, Stratakis, Constantine A, Mercado-Asis, Leilani, Pacak, Karel

“…Pheochromocytoma and paraganglioma (PHEO/PGL) are rare neuroendocrine tumors which may cause potentially life-threatening complications, with about a third of…”
Get full text

Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors by Maxwell, Jessica E., MD, MBA, Sherman, Scott K., MD, Menda, Yusuf, MD, Wang, Donghong, MS, O'Dorisio, Thomas M., MD, Howe, James R., MD

“…Abstract Background Somatostatin receptor scintigraphy (SRS; octreoscan) is used in neuroendocrine tumors to locate the primary tumor site and delineate the…”
Get full text

Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs by Kwekkeboom, Dik J, Mueller-Brand, Jan, Paganelli, Giovanni, Anthony, Lowell B, Pauwels, Stanislas, Kvols, Larry K, O'Dorisio, Thomas M, Valkema, Roelf, Bodei, Lisa, Chinol, Marco, Maecke, Helmut R, Krenning, Eric P

“…A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with…”
Get full text

Presacral neuroendocrine tumors associated with the Currarino syndrome by Scott, Aaron T., Tessmann, Jonathon B., Braun, Terry, Brown, Bartley, Breheny, Patrick J., Darbro, Benjamin W., Bellizzi, Andrew M., Dillon, Joseph S., O'Dorisio, Thomas M., Alderson, Alice, Bennett, Bonita, Bernat, John A., Metz, David C., Howe, James R.

“…Currarino syndrome (CS) is an autosomal dominant syndrome caused by mutations in MNX1 and characterized by anorectal abnormalities, partial sacral agenesis,…”
Get full text

RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner by Hagen, Jussara, Muniz, Viviane P, Falls, Kelly C, Reed, Sara M, Taghiyev, Agshin F, Quelle, Frederick W, Gourronc, Francoise A, Klingelhutz, Aloysius J, Major, Heather J, Askeland, Ryan W, Sherman, Scott K, O'Dorisio, Thomas M, Bellizzi, Andrew M, Howe, James R, Darbro, Benjamin W, Quelle, Dawn E

“…Mechanisms of neuroendocrine tumor (NET) proliferation are poorly understood, and therapies that effectively control NET progression and metastatic disease are…”
Get full text

NANETS consensus guidelines for the diagnosis of neuroendocrine tumor by Vinik, Aaron I, Woltering, Eugene A, Warner, Richard R P, Caplin, Martyn, O'Dorisio, Thomas M, Wiseman, Gregory A, Coppola, Domenico, Go, Vay Liang W

Get full text